Nanjing Biosion Out-licenses Global Rights for Trop2 mAb to OBI Pharma
publication date: Dec 16, 2021
Biosion, a Nanjing-Delaware immunoncology company, out-licensed global rights for its anti-Trop2 humanized monoclonal antibody to Taiwan's OBI Pharma. OBI will conduct preclinical and clinical development plus commercialization of BSI04702 as an antibody drug conjugate along with other products. BSI04702 was created using Biosion's proprietary SynTracerTM HT-endocytosis platform, a high-throughput endocytosis screening application that identifies antibodies with high internalization rates. OBI Pharma will make upfront, milestone and royalty payments, though specific details were not disclosed. More details....
Stock Symbol: (TWO: 4174)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.